Health related quality of life and compliance in patients with rheumatoid arthritis treated with biologic subcutaneous drugs: a cross-sectional study
Translated title
Undersøgelse af helbredsrelateret livskvalitet og compliance hos reumatoid artrit patienter i en subkutan biologisk behandling
Author
Kristensen, Maria
Term
4. term
Publication year
2012
Submitted on
2012-05-31
Pages
25
Abstract
This study aimed to assess health-related quality of life and treatment adherence (compliance) among patients with rheumatoid arthritis (RA) using subcutaneous biologic drugs, and to explore whether dosing intervals are associated with these outcomes. In a cross-sectional design across eight Danish rheumatology outpatient clinics, adult RA patients (ACR 1987 criteria) completed a questionnaire including the Compliance Questionnaire Rheumatology (CQR) and the EuroQol (EQ-5D). Descriptive analyses and multiple linear regression models were performed with CQR and EQ-5D as outcomes. A total of 128 patients responded; 70.1% were women and the mean age was 56 years. Most were treated with adalimumab (46.8%) or etanercept (43.7%). The mean EQ-5D score was 0.729 (range 0.223–1.000), and the mean CQR score was 20.8 (range 1.8–63.2). There was a weak but statistically significant correlation between administration interval and CQR, while no significant association was found with EQ-5D. In regression analyses, older age was linked to worse CQR, female sex to lower EQ-5D, and higher education to better EQ-5D. Overall, quality of life was comparable to other RA studies but lower than in the general Danish population, and CQR scores were lower than reported among methotrexate-treated RA patients, suggesting adherence challenges. Other unmeasured factors may also influence these outcomes.
Formålet med dette studie var at undersøge helbredsrelateret livskvalitet og efterlevelse (compliance) blandt patienter med reumatoid artrit (RA), der behandles med subkutane biologiske lægemidler, og at afklare om doseringsintervaller hænger sammen med disse udfald. I et tværsnitsdesign rekrutteret fra otte danske reumatologiske ambulatorier udfyldte voksne RA-patienter (ACR 1987-kriterier) et spørgeskema bestående af Compliance Questionnaire Rheumatology (CQR) og EuroQol (EQ-5D). Der blev udført deskriptiv statistik og multiple lineære regressionsanalyser med CQR og EQ-5D som udfald. I alt besvarede 128 patienter spørgeskemaet; 70,1 % var kvinder, og gennemsnitsalderen var 56 år. De fleste blev behandlet med adalimumab (46,8 %) eller etanercept (43,7 %). Den gennemsnitlige EQ-5D-score var 0,729 (spænd 0,223–1,000), og den gennemsnitlige CQR-score var 20,8 (spænd 1,8–63,2). Der blev fundet en svag, men signifikant sammenhæng mellem administrationsinterval og CQR, mens der ikke sås en signifikant sammenhæng med EQ-5D. I regressionerne var højere alder forbundet med lavere CQR, kvindekøn med lavere EQ-5D, og højere uddannelse med bedre EQ-5D. Samlet lå livskvaliteten på linje med andre RA-studier, men under niveauet i den generelle danske befolkning, og CQR var lavere end rapporteret for methotrexatbehandlede RA-patienter, hvilket peger på efterlevelsesudfordringer. Andre faktorer uden for denne undersøgelse kan også have haft betydning.
[This apstract has been generated with the help of AI directly from the project full text]
Keywords